The Pineapple Express: An Overview of the Bayh-Dole Act

By SRAI News posted 17 days ago

  
image

 

The Pineapple Express: An Overview of the Bayh-Dole Act | 

 

In 1980, the Bayh-Dole Act filled a much-needed gap within the U.S. research enterprise, allowing universities to retain ownership of inventions created with federal funds and awards, rather than the ownership reverting to the federal government. With the current U.S. Federal funding instability, awareness of this policy and its implications in attempting to identify alternate funding streams is essential.

 


 

The Bayh-Dole Act of 1980 allows universities to retain ownership of inventions created with federal funds and awards, rather than the ownership reverting to the federal government. This has enabled universities to patent, license, and commercialize new technologies, accelerating the transition from laboratories to the marketplace. Under the Bayh-Dole Act, federal grantees may retain the patent rights to an invention created with federal support. The federal grantee may then use the invention itself or license the patent to an industry partner, thereby profiting from their work.

Prior to the Bayh-Dole Act, the United States had a different system for handling inventions originating from federally funded research. There were fragmented, agency-by-agency policies; each federal agency had its own patent policy — some allowed grantee ownership; most did not. For federal agencies such as NIH, NSF, and DoD, the government usually retained the patent rights, and as a result, discoveries often remained with the federal government rather than being further developed. Businesses faced an inefficient and inconsistent system. Companies were reluctant to engage or invest in technology. Consequently, commercialization rates were very low. By 1980, the U.S. government owned ~28,000 patents. However, fewer than 5% were licensed or used. Most inventions were essentially “shelved.” Further, universities had little reason to patent discoveries or to identify industry partners. Researchers rarely benefited financially. As a result, there was no infrastructure to support commercialization, such as today’s technology transfer offices. Private companies avoided development. Turning research into products can be cost-prohibitive, especially for medications. Without exclusive patent rights, companies could not protect their investments.

Imagine this scenario: a federally funded university lab discovers a promising cancer therapeutic. The government holds the patent. No company wants to invest in trials without exclusivity. So, the discovery never becomes a drug. The Bayh-Dole Act was designed to encourage innovation and the commercialization of research, to turn government-funded discoveries into marketable and useful products, and to promote collaboration between academia and industry.

The Act has had a substantial impact! The Bayh-Dole Act has accelerated commercial development of pharmaceuticals (new drugs and vaccines), has accelerated biotechnology start-ups, and has helped create university technology transfer offices (which became widespread after the law) to facilitate more interactions between academic institutions and commercial entities.

Notably, the Act created “march-in rights,” which allow a federal agency (such as the NIH or the Department of Energy) to step in and grant additional licenses to other companies, even without the patent holder’s permission. Thus, if an invention isn’t being used appropriately, the government can “march in” and make it available to itself or others. Although this has never been invoked, one can imagine the need during a pandemic or other national emergency.

The overall impact of the bipartisan Bayh-Dole Act on universities has included the emergence of technology transfer offices, increased patenting and licensing, accelerated university start-ups, increased collaboration with industry, a revenue stream for universities, and a translational avenue for researchers. The Act has created over 19,000 start-ups, supported millions of jobs, and has driven $1.9 trillion in economic growth thus far. The Bayh-Dole Act remains one of the most significant federal laws affecting university research operations.

While the act is nearly 50 years old, the relevance of Bayh-Dole is still most current. University technology transfer and patent offices remain robust due to the level of activity generated by investigators looking to take discoveries to market. In our current climate of funding challenges and restrictions, it is important to explore alternate funding streams. Commercialization remains an encouraging option for investigators, with revenue sharing options possible with institutions and external companies. Even a small discovery (cell line, new methodology) could be leveraged. Research administrators would be well-advised to understand the importance of the Bayh-Dole Act and how its use can aid their investigators and research teams.

AI Statement

AI tools were used for fact-checking the historical information in the article.


Authored by:

Mark Lucas, CRA
Chief Administrative Officer
Departments of Neurobiology and Computational Medicine
David Geffen School of Medicine, UCLA
SRAI Distinguished Faculty & SRAI Catalyst Feature Editor


#Catalyst
#October2026
#Operations&WorkflowManagement